ArticleScientific reports2026
Cellular miRNA-31 and miRNA-125b as predictors of remission and major disease improvement in patients with early rheumatoid arthritis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- WISP-3 promotes PDGF-B-mediated angiogenesis through suppression of let-7b-5p in rheumatoid arthritis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that impairs quality of life, highlighting the need for novel biomarkers for early diagnosis and improve disease management. This study explored the cellular microRNAs (miRNAs) profile in early RA to identify potential predictors of therapeutic response. We measured a panel of 768 miRNAs in peripheral blood mononuclear cells (PBMCs) from two early RA cohorts (< 6 months), stratified by sustained SDAI/CDAI remission and non-response to conventional therapy over 12 months. Initial screening identified 13 differentially expressed miRNAs (≥ 1.5-fold change), which were validated in an independent cohort comprising 59 early RA patients and 54 healthy controls. MiRNA levels were quantified by qPCR, and predictive performance was assessed by receiver operating characteristic (ROC) curve. Among the 13 candidates, baseline levels of miRNA-31 and miRNA-125b predicted SDAI/CDAI remission at 6 months. Moreover, changes in their expression after 1 month of therapy predicted Boolean2.0 remission and achievement of major disease improvement (≥ 85% reduction in disease activity) at 6 months. Higher baseline expressions of both miRNAs were consistently observed in patients who achieved remission. These findings suggest that cellular expression of miRNA-31 and miRNA-125b may serve as promising prognostic biomarkers for 6-month remission in early RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.